Most claims about KPV peptide benefits trace back to a single, well-defined property: KPV is the C-terminal tail of the hormone alpha-MSH, and that three-amino-acid fragment carries much of the parent molecule’s anti-inflammatory activity. The interesting part is how it does this, and how thin the human evidence still is. Nearly everything published on KPV comes from cell cultures and mouse models, not clinical trials.

New here? Start with the broader overview of peptides studied for inflammation, then use this page for the KPV specifics.

What KPV is: the C-terminal fragment of alpha-MSH

KPV is one of the shortest bioactive peptides in this field, just three amino acids: Lys-Pro-Val. It corresponds to residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH), and researchers isolated it to ask whether the anti-inflammatory power of the full hormone could be reduced to its tail (2).

The answer was largely yes. Much of alpha-MSH’s anti-inflammatory activity survives in the KPV fragment, but the mechanism shifts. The parent hormone works through melanocortin receptors; KPV appears to act mostly through a different, receptor-independent route (2).

Attribute	Detail
Class	Tripeptide (Lys-Pro-Val); C-terminal fragment of alpha-MSH
Studied for	Intestinal inflammation, skin inflammation, antimicrobial activity
Evidence tier	In-vitro and animal; no completed human efficacy trials
Legal status (US)	Not FDA-approved; sold for research use only

How KPV works: PepT1 uptake and NF-kB signaling

The most-cited KPV mechanism comes from work by Dalmasso and colleagues. They reported that nanomolar concentrations of KPV are taken up by intestinal epithelial and immune cells through PepT1, a di- and tripeptide transporter (1). (Evidence: in-vitro.)

PepT1 matters here for a specific reason. It sits mainly in the small intestine but is switched on in the colon during inflammatory bowel disease, so the same inflamed tissue that is the target also expresses the transporter that carries KPV inside (1). Once internalized, KPV inhibited activation of the NF-kB and MAP kinase pathways and reduced pro-inflammatory cytokine output. (Evidence: in-vitro.)

A separate study of the alpha-MSH family suggested KPV may also dampen interleukin-1-beta signaling rather than acting through melanocortin receptors (2). (Evidence: in-vitro / animal.) The two mechanisms are not mutually exclusive; both point to KPV interrupting inflammatory signaling downstream, inside the cell.

What KPV is studied for

Intestinal inflammation and experimental colitis

The strongest KPV signal is in animal models of colitis. Oral KPV reduced the severity of both DSS- and TNBS-induced colitis in mice, lowering weight loss, myeloperoxidase activity, and pro-inflammatory cytokine expression (1). (Evidence: animal.)

Later work tried to make oral delivery more efficient. Xiao and colleagues loaded KPV into hyaluronic-acid-functionalized nanoparticles and reported that treated mice recovered body weight and showed colon tissue “very similar” to healthy controls, with TNF-alpha driven back toward normal (3). (Evidence: animal.) This is delivery-system research, not a human trial, but it reinforces the colitis-model finding. KPV is one of several compounds examined in gut-inflammation models; the more heavily marketed BPC-157 is another often discussed in the same context.

Skin and wound-related inflammation

Because KPV inherits alpha-MSH anti-inflammatory chemistry, it is frequently discussed for skin and wound contexts. The mechanistic basis (NF-kB suppression, cytokine reduction) is documented, but published KPV-specific wound-healing data in humans is not established, and much of the marketing here outruns the evidence (2). (Evidence: in-vitro / mechanistic.)

Antimicrobial activity

Alpha-MSH and its C-terminal KPV fragment have shown activity against representative pathogens including Staphylococcus aureus and Candida albicans in laboratory assays (4). (Evidence: in-vitro.) This is an early and narrow finding, not a basis for any infection claim.

Research area	Proposed mechanism	Evidence maturity	Regulatory status (US)
Colitis / IBD models	PepT1 uptake; NF-kB and MAP kinase inhibition	Animal (DSS, TNBS)	Not FDA-approved
Skin / wound inflammation	alpha-MSH-derived cytokine suppression	In-vitro / mechanistic	Not FDA-approved
Antimicrobial	Direct activity vs bacteria and fungi	In-vitro	Not FDA-approved

KPV legal and research-use status in 2026

KPV has never been approved by the FDA for any indication. It has moved through the compounding-review process rather than the drug-approval one: it was placed on a restricted list, later removed when nominators withdrew, and is scheduled for a Pharmacy Compounding Advisory Committee review in July 2026. (Evidence: regulatory.)

None of that is the same as approval. Products labeled “research use only” are, by definition, not cleared for human use, and legal status varies by jurisdiction and keeps shifting. For a fuller picture of where compounds like this stand, see which research peptides are legal.

Key takeaways

• KPV is the C-terminal tripeptide of alpha-MSH, and it keeps much of that hormone’s anti-inflammatory activity in a three-amino-acid form (2).
• KPV enters cells through the PepT1 transporter and suppresses the NF-kB inflammatory pathway in intestinal and immune cells (1).
• The clearest efficacy signal is in mouse colitis models (DSS and TNBS), where oral KPV reduced inflammation markers (1).
• Nanoparticle delivery studies reinforced the colitis finding but remain animal research, not human proof (3).
• KPV is not FDA-approved and is sold for research use only, with regulatory status under active review in 2026.

Frequently asked questions

What are the main KPV peptide benefits reported in research?

In published studies, KPV’s main reported benefit is reducing inflammation, mostly in animal models of gut inflammation and in cell-based assays. These findings are preclinical, so they describe research potential rather than proven human results.

How does KPV reduce inflammation?

In cell studies, KPV is transported into intestinal and immune cells by PepT1, then blocks NF-kB and MAP kinase signaling, lowering pro-inflammatory cytokine production (1). Some work also points to interference with interleukin-1-beta activity (2).

Is KPV FDA-approved?

No. KPV is not approved by the FDA for any use. It is commonly sold for research use only and was under compounding-committee review in 2026.

Is there human clinical trial data on KPV?

There are no completed human efficacy trials for KPV. The evidence base is cell-culture and animal work, primarily rodent colitis models (1)(3).

How is KPV related to alpha-MSH?

KPV is the last three amino acids (residues 11-13) of alpha-MSH. Researchers isolated it to test whether the hormone’s anti-inflammatory effect could be captured in a smaller fragment (2).

What is KPV most studied for?

Intestinal inflammation is the best-studied area, with additional in-vitro work on skin inflammation and antimicrobial activity against Staphylococcus aureus and Candida albicans (1)(4).

KPV sits within the melanocortin and anti-inflammatory peptide family, where its identity as the C-terminal Lys-Pro-Val fragment of alpha-MSH links it to receptor-independent signaling, PepT1-mediated uptake, and downstream suppression of NF-kB, MAP kinase, and cytokines such as TNF-alpha, findings drawn from DSS and TNBS colitis models and hyaluronic-acid nanoparticle delivery systems; Compound Universe tracks each of these threads against the primary literature so the summary reflects evidence maturity rather than marketing.

The honest read on KPV peptide benefits is that the mechanism is genuinely interesting and the animal data on gut inflammation is real, but the human evidence is not there yet, and the compound remains research-use-only rather than an approved therapy. That gap between mechanism and proof is exactly what Compound Universe tracks as the science develops.

References

1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008. PMID 18061177 / PMC2431115.
2. Getting SJ, Schioth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. J Pharmacol Exp Ther. 2003. PMID 12750433.
3. Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. 2017. PMID 28143741 / PMC5498804.
4. Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000. PMID 10670585.
5. FDA Pharmacy Compounding Advisory Committee, Section 503A bulk drug substances review of KPV (scheduled July 2026); KPV not FDA-approved for any indication.

Compare next: Compound Universe BPC-157 research summary | the anti-inflammatory peptide overview | research-peptide legal status